Age-Related Macular Degeneration: Therapy

The disease is still considered difficult to treat today! A causal therapy of manifest dry AMD does not exist so far.The treatment of macular degeneration is based on the following pillars:

General measures

  • Nicotine restriction (refraining from tobacco use; smoking, also affects the risk of dry to wet form of AMD).
  • Review of permanent medication due topossible effect on the existing disease.
  • Avoidance of environmental stress:
    • Radiation exposure – in the case of intense sunlight (UV-A, UV-B) → Limit or avoid sunbathing as well as visits to solariums.
      • Sunglasses protect the retina as well as the sensitive macula from UV rays.
    • Caution in discotheques: here it can be damaged by laser use.

Conventional non-surgical therapy methods

  • In some patients with wet macular degeneration, laser photocoagulation can prevent or slow disease progression. If the vascular neoplasms are sufficiently distant from the macula (yellow spot), they can be obliterated by laser coagulation with the argon-green laser using a heat effect. However, this is only the case in 15% of patients suffering from AMD with new vessel formation. The disadvantage of this is that when the retina is lasered, healthy tissue is also destroyed. The scar in the area, however, leads to a scotoma (visual field loss).
  • Photodynamic therapy (PDT) represents a promising therapeutic concept based on a photochemical effect induced by laser irradiation. In a two-step process, a so-called photosensitizer is first injected intravenously, which accumulates in pathologic vascular growths in the macula. Irradiation with a laser matched to the absorption of the photosensitizer activates it.The activation closes the proliferating blood vessels of the macula. The treatment spares surrounding tissue and especially the remaining healthy sensory cells, since no thermal effects occur during irradiation.
  • Injection of a growth factor inhibitor (VEGF inhibitor): growth factors are endogenous substances that stimulate, for example, the formation of new vessels. In macular degeneration the growth factor VEGF – “vascular endothelial growth factor” – plays a special role. By injecting a VEGF inhibitor (aflibercept, bevazizumab, pegaptanib and ranibizumab), the process of new vessel formation in wet AMD can be slowed down.

Regular checkups

  • Regular ophthalmological check-ups

Nutritional medicine